The PolyKye™ Platform: Predictive AI for Botanical Drug Discovery
PolyKye™ is Canurta’s proprietary AI discovery engine, built to accelerate the identification, optimization, IP-backed production and blockchain traceability of novel multi-target botanical drug candidates, starting with rare polyphenols and expanding into new chemical entities.
How PolyKye™ Powers Canurta’s Pipeline
PolyKye™ embeds predictive insights directly into early-stage R&D, guiding which bioactive compounds are prioritized, how they’re formulated, and what disease pathways they’re designed to target.
Patented Technology
Molecule Library
Polykye™
Development-Ready Compounds
CMC
Botanical Therapies
Clinical Validation and Precision Modelling
Applies proprietary extraction, biosynthesis, and seed activation methods to generate novel polyphenols and drug-like compounds. Forming the foundation of Canurta’s development engine.
A curated set of both sourced and AI-generated compounds, ready for screening, optimization, and advancement.
Filters and advances only the most promising candidates, those that meet thresholds for potency, manufacturability, and clinical relevance.
A refined set of high-potential candidates selected for advancement, based on validated bioactivity, manufacturability, and therapeutic relevance. These compounds meet the thresholds to enter formulation and regulatory development.
Standardizes and scales each compound's production using GMP-compliant processes, GAP-sourced inputs, and molecular fingerprinting to ensure quality and traceability.
Translates validated compounds into therapeutic formulations, ready for clinical study, regulatory advancement, or commercialization.
Applies disease-specific data and in silico modeling to optimize therapeutic impact and prepare candidates for targeted clinical trials.
Polykye™ is fully Integrated into our Development Process
Select high-potential candidates faster
with a stronger biological rationale
Assess bioactivity across multiple pathways
such as inflammation, oxidative stress, and neurodegeneration
Model drug-like properties
including ADMET (absorption, distribution, metabolism, excretion, toxicity
Design optimized formulations
based on predicted synergy between botanical actives
Align discovery with clinical goals
such as reducing neuroinflammation or supporting motor neuron health in ALS
Blockchain-Enabled Traceability for Regulatory Confidence
De-risks clinical advancement and streamlines market readiness. Each production lot is linked to a verifiable digital trail that includes:
Raw material origin and handling
Manufacturing records and CMC documentation
Molecular fingerprinting and quality control outputs
Our Manufacturing is Built on a Growing Portfolio of 23 global patents
These systems yield therapeutic-grade compounds and act as modular IP assets for licensing or collaboration
Precision extraction
isolating rare, pharmacologically active compounds
Biosynthetic techniques
support high-purity, scalable compound production
Lab-synthesizable molecular structures
candidates can be produced and validated experimentally
Seed Activation
optimize bioactive expression at the cultivation level